1) Partnered with Eisai for BAN2401 for treatment of Alzheimer’s disease. Eisai entered partnership with Biogen regarding BAN2401 in 2014
2) AbbVie in-licensed BAN0805 in late 2018 and develops the antibody with the designation ABBV-0805
3) Dementia and cognitive impairment associated with Down’s syndrome
BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development. Project portfolio as of June 30, 2020.